AZD5305, also known as saruparib, is AstraZeneca's next-generation PARP inhibitor designed with a primary objective: achieving superior PARP1 selectivity over first-generation agents. Unlike olaparib and other earlier inhibitors, which exhibit activity across multiple PARP family members, AZD5305 is engineered to target PARP1 with greater precision — a distinction with significant clinical implications for tolerability and therapeutic index.

The mechanism of action centres on synthetic lethality — the principle that cancer cells harbouring homologous recombination deficiencies, such as those caused by BRCA1 or BRCA2 mutations, become selectively vulnerable when PARP-mediated DNA repair is simultaneously inhibited. By trapping PARP1 at sites of DNA damage, the compound prevents repair of single-strand breaks, which in BRCA-mutant cells cannot be resolved through homologous recombination, ultimately leading to cell death.

The strategic rationale for enhanced PARP1 selectivity is rooted in tolerability. First-generation PARP inhibitors are associated with haematological toxicities — including anaemia and thrombocytopenia — partly attributable to off-target PARP2 inhibition in haematopoietic progenitor cells. A more selective PARP1 inhibitor holds the potential to maintain or enhance the synthetic lethality signal in homologous recombination-deficient tumors while reducing the toxicity burden that limits dosing and combination strategies with first-generation agents.

This mechanistic refinement positions AZD5305 not merely as an incremental improvement, but as a platform for exploring combination regimens — including with DNA damage response agents, immunotherapy, and targeted therapies — that may have been dose-limited with earlier PARP inhibitors.

The advancement of AZD5305 into Phase III clinical evaluation represents a significant milestone in the evolution of PARP inhibitor therapy. Phase III trials are the pivotal studies that regulatory agencies such as the FDA and EMA require for marketing authorisation, meaning AZD5305 is now on the regulatory pathway toward potential approval in BRCA-mutant solid tumors.

The choice of BRCA-mutant solid tumors as the Phase III population reflects the well-established synthetic lethality rationale in this biomarker-selected group. BRCA1 and BRCA2 mutations impair homologous recombination repair, creating a dependency on PARP-mediated single-strand break repair that PARP inhibitors exploit. This population has been clinically validated by first-generation PARP inhibitors across breast, ovarian, prostate, and pancreatic cancers.

AZD5305's Phase III entry signals that AstraZeneca has accumulated sufficient Phase I/II evidence — including safety, tolerability, and preliminary efficacy data — to justify the substantial investment of a pivotal trial. This represents a critical inflection point for the compound and for the broader narrative of next-generation PARP inhibitor development. The pharmaceutical industry is watching this programme closely as a potential template for next-generation DNA damage response agent development.

For R&D teams, IP professionals, and competitive intelligence analysts tracking this space, understanding the patent landscape around AZD5305 — including composition of matter filings, method of treatment claims, and combination therapy patents — is essential for informed decision-making. PatSnap's analytics platform provides the tools to navigate this complex IP environment with precision.